FDA review of dupilumab for chronic spontaneous urticaria

Published Date: 13 Mar 2023

The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

2.

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

3.

Treatment of Oligometastatic EGFR-Mutant Lung Cancer

4.

According to a study, breast cancer cells work together to physically breach barriers and proliferate.

5.

Nearly 6 Million Deaths From Five Major Cancer Types Averted Since 1975


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot